TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06029075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS Sham
Description: Sham tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS Sham
Description: Sham tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS Sham
Description: Sham tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS 10Hz
Description: 10Hz tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS 10Hz
Description: 10Hz tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS 10Hz
Description: 10Hz tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS 20Hz
Description: 20Hz tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS 20Hz
Description: 20Hz tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS 20Hz
Description: 20Hz tACS will applied to the brain through the scalp for 20 minutes.
Study: NCT05836142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: progressive pressure release
Description: Bilateral progressive pressure release in latent trigger points of the Flexor digitorum Brevis Muscle
Study: NCT04674514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 orally once daily, every 28 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 orally once daily, every 28 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rd
Description: Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone administered at a dose of 40 mg (or 20 mg for patients\>75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle.
Study: NCT06401824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab
Description: Sacituzumab govitecan 10mg/kg intravenous day 1 and day 8 of a 21-day cycle, + bevacizumab 15 mg/kg iv day 1 of a 21-day cycle till unacceptable toxicity or disease progression.
Study: NCT06310486

Intervention type: OTHER
Intervention: Drowning-related OHCA
Description: These patients were involved in a drowning incident (submersion or immersion in liquid) and experienced out-of-hospital cardiac arrest (OHCA), defined as being unconscious and not breathing normally at any time in the prehospital setting. Some of these patients may die as a consequence of the submersion injury (fatal drowning), while others may survive (non-fatal drowning).

Intervention type: OTHER
Intervention: Drowning-related OHCA
Description: These patients were involved in a drowning incident (submersion or immersion in liquid) and experienced out-of-hospital cardiac arrest (OHCA), defined as being unconscious and not breathing normally at any time in the prehospital setting. Some of these patients may die as a consequence of the submersion injury (fatal drowning), while others may survive (non-fatal drowning).

Intervention type: OTHER
Intervention: Drowning-related non-OHCA
Description: These patients were involved in a drowning incident (submersion or immersion in liquid) but did not experience an OHCA. Some of these patients may die as a consequence of the submersion injury (fatal drowning), while others may survive (non-fatal drowning).

Intervention type: OTHER
Intervention: Drowning-related non-OHCA
Description: These patients were involved in a drowning incident (submersion or immersion in liquid) but did not experience an OHCA. Some of these patients may die as a consequence of the submersion injury (fatal drowning), while others may survive (non-fatal drowning).
Study: NCT06240221

Intervention type: DEVICE
Intervention: Elevation Spine Saber-C System
Description: Device: Elevation Spine Saber-C System Elevation Spine Saber-C System will be fixated between C2 through T1 according to surgeon standard of care at clinical practices through the United States.
Study: NCT05610033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtaCor StealthTrac Lead
Description: Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
Study: NCT05377268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LH Protocol
Description: Patients will be randomized and data interpreters will be blinded to two, randomized, alternating 14-day protocols where the patients will be advised by the nurse educator verbally to inject insulin in sites of subclinical lipohypertrophy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LH Protocol
Description: Patients will be randomized and data interpreters will be blinded to two, randomized, alternating 14-day protocols where the patients will be advised by the nurse educator verbally to inject insulin in sites of subclinical lipohypertrophy
Study: NCT05241392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B7-H3-targeting CAR-T cells
Description: Patients will be treated with anti-B7-H3 autologous CAR-T cells that are delivered into the intracranial tumor resection cavity or ventricular system using an Ommaya device.
Study: NCT06020677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-WebTIPS
Description: This mobile health application includes cultural adaption and grounding of a previously developed and tested tailored mHealth intervention, WebTIPS. LWebTIPS is a culturally adapted mHealth intervention that is aimed at the child and parent and strives to improve clinical outcomes and patient experience of Latinx children. Tailoring variables include: Simpatia, Religiosity and Familism.
Study: NCT05489835

Intervention type: BEHAVIORAL
Intervention: Nutritional counseling
Description: Nutritional counseling
Study: NCT04971291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: AXS-05 taken twice daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion SR
Description: Bupropion taken twice daily for 6 weeks
Study: NCT05230589

Intervention type: DRUG
Intervention: Oral semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study: NCT05217121

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions, the probe will be covered with a sterile sheath and a 22G, 80 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles, the needle will be punctured and 5 ml of saline will be injected into the postero-lateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified-thoracolumbar interfascial plane block
Description: US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 15 mL will be injected in each side (30 ml totally).
Study: NCT06000995

Intervention type: OTHER
Intervention: Survey Questions
Description: Thirty questions generally consist of three parts; In the first part, there are 8 questions containing the personal information of the doctors (age, gender, title, institution, etc.). In the second part, 13 questions were included in order to make a general assessment such as the sedative agents used by the doctors before and during the bronchoscopy procedure and the satisfaction with the sedative method used. In the third part, 9 questions were given to determine the preferred follow-up methods during the procedure.
Study: NCT05699161

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Adipose-derived stromal vascular fraction cells
Description: Published minimal clinically important differences (MCID) for PDQ-39; MDS-UPDRS; and levo-dopa equivalent dose and changes in the levels of blood proteins (L-1beta, IL-2, IL-6, IL-10, and TNF-alpha) in 10 patients after 12 months of treatment with SVF cells.
Study: NCT06316700

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional supplement
Description: A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin placebo
Study: NCT04957342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: amnion-chorion membrane
Description: allograft to be placed on palate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sutures
Description: Sutures (e.g. interrupted, crisscross compression) to be placed on palate
Study: NCT06174844

Intervention type: OTHER
Intervention: No intervention applied
Description: No intervention applied: data will only be collected in the indicated sampling periods from patients admitted to the participating hospitals.

Intervention type: OTHER
Intervention: No intervention applied
Description: No intervention applied: data will only be collected in the indicated sampling periods from patients admitted to the participating hospitals.
Study: NCT05327413

Intervention type: OTHER
Intervention: CT and MRI
Description: CT and MRI were conducted to measure the femoral external rotation
Study: NCT05449626

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment
Description: The Standardized Mini-Mental Test and Clinical Dementia Rating Scale will be administered by the physician to the healthy individuals with dementia to be included in the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment
Description: The Standardized Mini-Mental Test and Clinical Dementia Rating Scale will be administered by the physician to the healthy individuals with dementia to be included in the study.
Study: NCT05151003

Intervention type: OTHER
Intervention: Data collection
Description: Collection and analysis of data related to AKI epidemiology, treatment and outcomes
Study: NCT05851742

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS 50-280 HZ frequency and a pulse duration of 50 us for 10 minutes along with 10 minutes myofascial release.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial trigger point release
Description: Release of trigger points
Study: NCT06158542

Intervention type: PROCEDURE
Intervention: Spinal Anesthesia
Description: After standard monitoring, the patient is placed in a sitting position for site marking and administration of anesthesia. The line connecting the upper border of the right and left iliac crests through conventional palpation of anatomical landmarks (Tuffier line) is identified as the entry point at the L3-L4 interspinous space or L2-L3 interspace. For patients in whom spinal entry is successful, spinal anesthesia is provided with the appropriate dose and types of local anesthetics (intrathecal 10-12 mg bupivacaine with the addition of 15-25 mcg fentanyl). After completing the procedure and placing the patient in the supine position, the block level is determined 10 minutes post-procedure using the ice test/pinprick test. Blocks reaching the T4-T6 level are considered successful.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sampling
Description: Preoperatively, syndecan-1 serum levels will be investigated from the blood sample taken before cesarean section.
Study: NCT05376215

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental hearing aid
Description: This hearing aid is a receiver-in-canal style hearing aid which can be programmed and adjusted by proprietary software and by use with a mobile application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental hearing aid
Description: This hearing aid is a receiver-in-canal style hearing aid which can be programmed and adjusted by proprietary software and by use with a mobile application.
Study: NCT04880785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]
Description: change of current antiretroviral treatment to DTG 50 mg/3TC 300 mg QD
Study: NCT06288620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: Preoperative US-guided microwave ablation of breast cancer
Study: NCT05796908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aptis PRUJ Prosthesis
Description: A prosthetic implant for replacement of the proximal radial ulna joint.
Study: NCT05929716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR T leukapheresis
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Given by IV (vein)
Study: NCT05470920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Decision Aid
Description: Decision aid followed by an appointment with an oncologist. Will complete surveys/questionnaires

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Test Genetic Counseling
Description: Receive pretest counseling with a genetic counselor. Will complete surveys/questionnaires
Study: NCT04027699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mini-bolus
Description: * First injection of 2ml/kg (saline solution)~* Second injection of 18ml/kg (saline solution)
Study: NCT05949619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M02D1
Description: Administration by intravenous infusion
Study: NCT05952440

Intervention type: OTHER
Intervention: Tapering and/or discontinuation of treatment based on AI-guidance
Description: After synovial tissue biopsy, pharmacological treatment (cDMARDs or bDMARDs) are tapered first and then bDMARDs and/or cDMARDs are discontinued based on AI-guidance

Intervention type: OTHER
Intervention: No tapering and/or discontinuation of treatment based on AI-guidance
Description: Ongoing therapeutic are not changed (tapered or discontinued) after synovial biopsy performance based on AI-guidance

Intervention type: OTHER
Intervention: Tapering and/or discontinuation of treatment based on standard of care
Description: After synovial tissue biopsy, pharmacological treatment (cDMARDs or bDMARDs) are tapered first and then bDMARDs and/or cDMARDs are discontinued based on standard of care

Intervention type: OTHER
Intervention: Tapering and/or discontinuation of treatment based on standard of care
Description: After synovial tissue biopsy, pharmacological treatment (cDMARDs or bDMARDs) are tapered first and then bDMARDs and/or cDMARDs are discontinued based on standard of care

Intervention type: OTHER
Intervention: No tapering and/or discontinuation of treatment based on standard of care
Description: Ongoing therapeutic are not changed (tapered or discontinued) after synovial biopsy performance based on standard of care

Intervention type: OTHER
Intervention: No tapering and/or discontinuation of treatment based on standard of care
Description: Ongoing therapeutic are not changed (tapered or discontinued) after synovial biopsy performance based on standard of care
Study: NCT06186076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX-221
Description: TRX-221 oral dose as defined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX-221
Description: TRX-221 oral dose as defined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX-221
Description: TRX-221 oral dose as defined
Study: NCT06460675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autogenic Inhibition Muscle Energy Technique
Description: No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per weeks for 3 weeks (40 Min per Session)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenic Inhibition Muscle Energy Technique
Description: No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per weeks for 3 weeks (40 Min per Session)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciprocal Inhibition Muscle Energy Technique
Description: No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per week for 3 weeks (40 Min per Session)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reciprocal Inhibition Muscle Energy Technique
Description: No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per week for 3 weeks (40 Min per Session)
Study: NCT05442255

Intervention type: OTHER
Intervention: Toxicological analysis
Description: Automated enzymatic assays Automated Immunoassay Urine Screening High Resolution Toxicological Screening
Study: NCT04778436

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: T7082
Description: Patients will take food supplementation for 12 months. For each patient : 5 visits with ophthalmogist and 6 phone call
Study: NCT04800562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS499
Description: PCS499 900mg twice a day with food

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator
Study: NCT05635799

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of walking on flat ground
Description: Analysis of walking on flat ground under different environmental conditions (visit 1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of walking on flat ground
Description: Analysis of walking on flat ground under different environmental conditions (visit 1)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital Anxiety Disorder Questionnaire
Description: performed during the inclusion visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety Disorder Questionnaire
Description: performed during the inclusion visit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of walking on slopes
Description: All assessments will be identical to the flat walking analysis: flat walking will be replaced by slope walking for all environmental conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of walking on slopes
Description: All assessments will be identical to the flat walking analysis: flat walking will be replaced by slope walking for all environmental conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group interview with a sociologist
Description: Virtual reality feedback, accompanied by a confrontation of the patients' subjective experiences (group of 5 to 10 people)
Study: NCT04945668

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modified technique for pericapsular nerve group block
Description: with the patient in the supine position, ultrasound probe in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus. In this view, the ilio pubic eminence (IPE), the iliopsoas muscle and tendon will be observed. A spinal needle will be inserted from lateral to medial in an in-plane approach to place the tip between the psoas tendon and the pubic ramus. Fluoroscopic image will be taken to confirm the needle tip position in the target site. Following negative aspiration, 15 ml dye will be injected in 5-mL increments while observing for adequate spread using fluoroscopy followed by 15ml local anesthetic
Study: NCT04194359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine
Description: Humanized PD-1 antibody (Sintilimab, IBI308)+bevacizumab+oxaliplatin+capecitabine
Study: NCT04986306

Intervention type: PROCEDURE
Intervention: SLNB + ALND
Description: Patients who received neoadjuvant chemotherapy will undergo SLNB+ALND to evaluate the feasibility of SLNB
Study: NCT05043714

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NG-641 in combination with Nivolumab
Description: NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.~Nivolumab is a human monoclonal antibody that targets the PD-1 cluster of differentiation 279 cell surface membrane receptor.
Study: NCT05155202

Intervention type: DRUG
Intervention: Antihypertensive Agents
Description: Administration of intravenous Nicardipine or Urapidil

Intervention type: DRUG
Intervention: Antihypertensive Agents
Description: Administration of intravenous Nicardipine or Urapidil
Study: NCT06147479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CS-ADL (Cognitive stimulation in Activities of Daily Living)
Description: CS-ADL sessions are delivered once weekly, for seven weeks. Sessions last approximately 2 hours. Sessions are themed around domains of everyday activities, for example 'Morning routine', ' Domestic Activities', 'Leisure'. Activities in each session follow this theme. A typical session begins with introductions, reality orientation, a group song and discussion of the news of the week. This is followed by a physical activity/game and ADL-focused cognitive stimulation activities. These activities include the identification and categorization of everyday items, discussion, reminiscence, planning and sequencing of ADLs and the completion of everyday writing/calculation tasks. This is followed by practice of an ADL. Examples of activities include making a breakfast, a simple gardening activity or sorting laundry. The session then ends with a summary and repeat of the group song, and a plan for the next session.
Study: NCT05071365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early access to virtual resources
Description: Single arm study. Participants are given access to self help videos for the management of plantar fasciitis while they are on the waiting list